407 related articles for article (PubMed ID: 28703931)
1. Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.
Osawa K; Nakanishi R; Win TT; Li D; Rahmani S; Nezarat N; Sheidaee N; Budoff MJ
Clin Cardiol; 2017 Oct; 40(10):807-813. PubMed ID: 28703931
[TBL] [Abstract][Full Text] [Related]
2. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
Guimarães PO; Pokorney SD; Lopes RD; Wojdyla DM; Gersh BJ; Giczewska A; Carnicelli A; Lewis BS; Hanna M; Wallentin L; Vinereanu D; Alexander JH; Granger CB
Clin Cardiol; 2019 May; 42(5):568-571. PubMed ID: 30907005
[TBL] [Abstract][Full Text] [Related]
4. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
[TBL] [Abstract][Full Text] [Related]
5. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
6. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of PROACT Xa: A randomized, multicenter, open-label, clinical trial to evaluate the efficacy and safety of apixaban versus warfarin in patients with a mechanical On-X Aortic Heart Valve.
Jawitz OK; Wang TY; Lopes RD; Chavez A; Boyer B; Kim H; Anstrom KJ; Becker RC; Blackstone E; Ruel M; Thourani VH; Puskas JD; Gerdisch MW; Johnston D; Capps S; Alexander JH; Svensson LG
Am Heart J; 2020 Sep; 227():91-99. PubMed ID: 32693197
[TBL] [Abstract][Full Text] [Related]
8. Apixaban versus warfarin in patients with atrial fibrillation.
Granger CB; Alexander JH; McMurray JJ; Lopes RD; Hylek EM; Hanna M; Al-Khalidi HR; Ansell J; Atar D; Avezum A; Bahit MC; Diaz R; Easton JD; Ezekowitz JA; Flaker G; Garcia D; Geraldes M; Gersh BJ; Golitsyn S; Goto S; Hermosillo AG; Hohnloser SH; Horowitz J; Mohan P; Jansky P; Lewis BS; Lopez-Sendon JL; Pais P; Parkhomenko A; Verheugt FW; Zhu J; Wallentin L;
N Engl J Med; 2011 Sep; 365(11):981-92. PubMed ID: 21870978
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
[TBL] [Abstract][Full Text] [Related]
10. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
[TBL] [Abstract][Full Text] [Related]
12. Apixaban versus warfarin in evaluation of progression of atherosclerotic and calcified plaques (prospective randomized trial).
Win TT; Nakanishi R; Osawa K; Li D; Susaria SS; Jayawardena E; Hamal S; Kim M; Broersen A; Kitslaar PH; Dailing C; Budoff MJ
Am Heart J; 2019 Jun; 212():129-133. PubMed ID: 31002997
[TBL] [Abstract][Full Text] [Related]
13. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.
van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ;
Trials; 2015 Sep; 16():393. PubMed ID: 26340977
[TBL] [Abstract][Full Text] [Related]
14. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy: Insights From the ARISTOTLE Trial.
Al-Khatib SM; Mulder H; Wojdyla D; Lopes RD; Wallentin L; Alexander JH; Hijazi Z; Goto S; Granger CB
Circ Arrhythm Electrophysiol; 2021 Mar; 14(3):e009614. PubMed ID: 33657831
[No Abstract] [Full Text] [Related]
15. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin.
Vinereanu D; Lopes RD; Mulder H; Gersh BJ; Hanna M; de Barros E Silva PGM; Atar D; Wallentin L; Granger CB; Alexander JH;
Stroke; 2017 Dec; 48(12):3266-3273. PubMed ID: 29089455
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.
Hijazi Z; Hohnloser SH; Andersson U; Alexander JH; Hanna M; Keltai M; Parkhomenko A; López-Sendón JL; Lopes RD; Siegbahn A; Granger CB; Wallentin L
JAMA Cardiol; 2016 Jul; 1(4):451-60. PubMed ID: 27438322
[TBL] [Abstract][Full Text] [Related]
17. Clinical Performance of Apixaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Direct Electrical Current Cardioversion: A Prospective Propensity Score-Matched Cohort Study.
Rago A; Papa AA; Cassese A; Arena G; Magliocca MCG; D'Onofrio A; Golino P; Nigro G; Russo V
Am J Cardiovasc Drugs; 2019 Aug; 19(4):421-427. PubMed ID: 30838557
[TBL] [Abstract][Full Text] [Related]
18. Apixaban in Patients With Atrial Fibrillation After Transfemoral Aortic Valve Replacement.
Seeger J; Gonska B; Rodewald C; Rottbauer W; Wöhrle J
JACC Cardiovasc Interv; 2017 Jan; 10(1):66-74. PubMed ID: 27916486
[TBL] [Abstract][Full Text] [Related]
19. CKD Progression in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation Treated With Apixaban Versus Warfarin.
Wetmore JB; Yan H; Herzog CA; Weinhandl E; Reyes JL; Roetker NS
Am J Kidney Dis; 2021 Aug; 78(2):180-189. PubMed ID: 33421454
[TBL] [Abstract][Full Text] [Related]
20. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
Cowper PA; Sheng S; Lopes RD; Anstrom KJ; Stafford JA; Davidson-Ray L; Al-Khatib SM; Ansell J; Dorian P; Husted S; McMurray JJV; Steg PG; Alexander JH; Wallentin L; Granger CB; Mark DB
JAMA Cardiol; 2017 May; 2(5):525-534. PubMed ID: 28355434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
